Isolation and Characterization of Endothelial Colony Forming Cells (ECFCs) in Patients Diagnosed With Von Willebrand Disease, Acquired Von Willebrand Syndrome and Healthy Subjects
This observational study, sponsored by Fondazione IRCCS Ca' Granda, aims to elucidate the behavior of ECFCs in patients with von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS) compared to healthy controls. The findings may provide insights into the cellular and molecular alterations associated with VWD, potentially leading to novel therapeutic strategies. The market for VWD treatments is significant, with a growing demand for innovative therapies addressing the underlying mechanisms of bleeding disorders. Competitive implications include the potential for new entrants focusing on gene therapy and cellular therapies targeting VWF deficiencies. Diligence considerations should include the study's design, patient recruitment, and the robustness of the data collection methods.
Indication: Von Willebrand Disease (VWD)
Modality: gene therapy
Target: Endothelial Colony Forming Cells (ECFCs) and von Willebrand Factor (VWF) production and secretion mechanisms.
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Endothelial Colony Forming Cells (ECFCs) and von Willebrand Factor (VWF) production and secretion mechanisms.
View original source fields
Condition raw: Von Willebrand Disease (VWD), Acquired Von Willebrand Disease
Condition normalized: Von Willebrand Disease (VWD), Acquired Von Willebrand Disease
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Endothelial Colony Forming Cells (ECFCs) and von Willebrand Factor (VWF) production and secretion mechanisms.
Target normalized: Endothelial Colony Forming Cells (ECFCs) and von Willebrand Factor (VWF) production and secretion mechanisms.